PRACTICAL GUIDE · PG-04
BPC-157 Quick Reference Sheet
PG-04 · 05 August 2026
| Research areas | Regenerative & Repair · Cardiovascular & Vascular Health |
|---|---|
| Forms | Lyophilised vial · enteric capsule · arginate capsule 500 mcg · nasal spray 30 mg/30 mL |
| Appearance | White to off-white powder or cake; fractured cake is normal |
| Solvent | Bacteriostatic water; 0.5–1% acetic acid if slow; no DMSO |
| Supplied as | 5, 10, 15 or 20 mg in a 3 mL vial |
| Working concentration | 2, 4, 5 or 8 mg/mL — the fill gives a whole number |
| Concentration limits | 3 mL vial sets the floor; at 6.7 mg/mL a 250 mcg draw is under 4 units |
| Dissolution | 2–5 minutes, up to 10 for some lots; cake may sit intact first |
| Solution appearance | Clear to very slightly opalescent, colourless to very pale yellow |
| Published dosing | No randomised controlled human trial; no amount established |
| Circulating practice | 250–500 mcg subcutaneous, once or twice daily |
| Duration and cycling | Blocks of 4–8 weeks with breaks |
This content is for members only
Join ARC to read the rest of this page, and everything else in the research library.
Join MembershipAlready a member? Log in